Dr. Hormigo on the Current Treatment Landscape of Glioblastoma

In Partnership With:

Partner | Cancer Centers | <b>The Tisch Cancer Institute at Mount Sinai </b>

Adilia Hormigo, MD, PhD, discusses the current treatment landscape of glioblastoma.

Adilia Hormigo, MD, PhD, director of the Neuro-Oncology Program, professor of neurology, neurosurgery, and medicine, Tisch Cancer Institute, Mount Sinai Hospital, discusses the current treatment landscape of glioblastoma.

Glioblastoma is a grade 4 astrocytoma and is the most malignant and frequent form of glioma observed in patients, explains Hormigo.

Upon diagnosis, the standard of care treatment is chemoradiation, Hormigo says. However, survival rates remain poor.

Moreover, there is no established standard of care regimen for patients with recurrent glioblastoma as no therapies have demonstrated a prolonged survival benefit, continues Hormigo.

While bevacizumab (Avastin) is approved in patients with glioblastoma who have progressed following prior therapy, research efforts should be aimed at developing additional therapies and determining which subsets of patients are likely to respond to the available options, concludes Hormigo.